Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001193125-19-161327
Filing Date
2019-05-30
Accepted
2019-05-30 16:28:23
Documents
47
Period of Report
2019-05-30

Document Format Files

Seq Description Document Type Size
1 6-K d753121d6k.htm 6-K 13782
2 EX-99.1 d753121dex991.htm EX-99.1 193490
3 EX-99.2 d753121dex992.htm EX-99.2 78314
4 EX-99.3 d753121dex993.htm EX-99.3 73680
11 GRAPHIC g753121g11o33.jpg GRAPHIC 6200
  Complete submission text file 0001193125-19-161327.txt   1946881

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE DOCUMENT asnd-20190331.xml EX-101.INS 254758
6 XBRL TAXONOMY EXTENSION SCHEMA asnd-20190331.xsd EX-101.SCH 32124
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE asnd-20190331_cal.xml EX-101.CAL 43530
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE asnd-20190331_def.xml EX-101.DEF 82675
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE asnd-20190331_lab.xml EX-101.LAB 223592
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE asnd-20190331_pre.xml EX-101.PRE 158615
Mailing Address TUBORG BOULEVARD 12 HELLERUP G7 DK-2900
Business Address TUBORG BOULEVARD 12 HELLERUP G7 DK-2900 45 70 22 22 44
Ascendis Pharma A/S (Filer) CIK: 0001612042 (see all company filings)

EIN.: 000000000 | State of Incorp.: G7 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-36815 | Film No.: 19866884
SIC: 2834 Pharmaceutical Preparations